Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
Background: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug. Here, we systematically conducted the efficacy, safety, compliance, and pharmacoeconomic evaluation of intravitreal conbercept (IVC) compared with other treatments in patients with neovascular age-related macular de...
Saved in:
Main Authors: | Pengxiang Zhou (Author), Siqian Zheng (Author), Ente Wang (Author), Peng Men (Author), Suodi Zhai (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Profile of conbercept in the treatment of neovascular age-related macular degeneration
by: Lu XM, et al.
Published: (2015) -
Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Yinchen Shen, et al.
Published: (2022) -
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
by: Lorenzo Ferro Desideri, et al.
Published: (2023) -
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
by: Wang LP, et al.
Published: (2018) -
Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021)